CVRdatabase
Menu

Cymab ApS

Private limited companyCVR 39859173København NActive

Cymab ApS is a private limited company, based in København N, active in manufacture of pharmaceutical preparations, founded in 2018. Equity was negative at the end of 2025 (−DKK 20.2m). The company made a loss in both 2024 and 2025, most recently DKK 7.6m. 8 other companies in the database are registered at the same address.

Follow
PDF reportCompare

Key figures · financial year 2025

Gross profit−DKK 5.5m−179.9% vs. 2024
Net profit−DKK 7.6m−63.7% vs. 2024
Equity−DKK 20.2m−59.9% vs. 2024
Employees2latest month from CVR

What has changed

calculated from recorded figures and dates

Financials: 2025 against 2024

  • The loss grew: from DKK 4.6m to DKK 7.6m (2024 → 2025).

Employees

  • 1 fewer employees than a year earlier: 2 (07/2026) against 3 (07/2025).

Management and owners, last 24 months

  • Stepped down: Anne Reker Cordt (board member, 06/02/2026) and Anne Reker Cordt (director, 06/02/2026).

Calculated from the latest two annual reports in sequence and from registrations in CVR. A figure that is missing in either year gives no line, and we derive no figures.

Financial statements

Financial years 2020–2025 · amounts in DKK thousand

Equity and net profit

−DKK 25m−DKK 20m−DKK 15m−DKK 10m−DKK 5mDKK 0202020212022202320242025
EquityNet profit
Financial figures for Cymab ApS
202020212022202320242025Change
Revenue0not stated0not statednot statednot stated–
Gross profit−1,077−567−1,167−1,206−1,952−5,463−179.9%
Operating profit (EBIT)−1,080–−1,912−3,178−5,502−8,587−56.1%
Profit before tax−1,244−915−2,142−3,515−6,106−9,848−61.3%
Net profit−956−943−1,541−2,581−4,628−7,576−63.7%
Total assets3433835,1665,55612,6115,779−54.2%
Equity−2,959−3,902−5,443−8,024−12,651−20,227−59.9%
Liabilities3,3024,28410,60913,57925,26326,006+2.9%
Cash and cash equivalents52394,1251888,4581,496−82.3%
Average number of employees–122330%

Source: annual reports filed with the Danish Business Authority (XBRL). Figures for the company (not the group); change is the latest year against the year before. “–” means the figure is not stated in the annual report. Revenue is not stated for 2021, 2023, 2024, 2025: smaller companies may omit it, and we do not derive it from other figures.

Download the figures as CSV · free with an account, amounts in whole DKK

−DKK 6m−DKK 4m−DKK 2mDKK 0DKK 2m202020212022202320242025
Gross profitMedian, the industry (59 companies)

Signals from the financial statements

calculated from the 2025 figures

  • Negative equity

    Equity was −DKK 20.2m at the end of 2025.

    How is this calculated?

    Equity in the latest annual report is below zero.

  • Loss for 6 years in a row

    Net result has been negative in 2020–2025.

    How is this calculated?

    Net result is negative in the two or more latest annual reports in a row.

The signals are rules applied to the figures in the annual reports. They are not an assessment or credit rating of the company. See Data and method.

Annual reports

6 financial years
Annual reports for Cymab ApS
Financial yearPeriodPublishedFigures forDocuments
202501/01/2025 – 31/12/202525/06/2026The companyPDF not statedXBRL
202401/01/2024 – 31/12/202416/06/2025The companyPDFXBRL
202301/01/2023 – 31/12/202329/06/2024The companyPDFXBRL
202201/01/2022 – 31/12/202230/06/2023The companyPDFXBRL
202101/01/2021 – 31/12/202121/06/2022The companyPDFXBRL
202001/01/2020 – 31/12/202011/06/2021The companyPDFXBRL

The figures from all the annual reports are shown on this page. The documents themselves (PDF and XBRL, the machine-readable edition) are downloaded with a Pro account: sign in or create a free account, and then choose Pro. XBRL is the edition the figures on the page are read from.

Employees

monthly figures from CVR
01234508/2309/2310/2311/2312/2301/2402/2403/2404/2405/2406/2407/2408/2409/2410/2411/2412/2401/2502/2503/2504/2505/2506/2507/2508/2509/2510/2511/2512/2501/2602/2603/2604/2605/2606/2607/26
Employees

Position in the industry

59 companies in the database

Comparison with the other companies in manufacture of pharmaceutical preparations based on the latest financial year.

Gross profit−DKK 5.5mNo. 47 of 57
Better than 18% of the companies in the industry
Equity−DKK 20.2mNo. 53 of 59
Better than 10% of the companies in the industry
Number of employees2No. 38 of 59
Better than 36% of the companies in the industry

Industry median: gross profit DKK 2.8m, net profit −DKK 2.2m, equity DKK 5.2m, 10 employees.

DKK 266kDKK 8.3mDKK 258mDKK 8bnDKK 79.6bn
Distribution of gross profit for 34 companies in the industry (latest financial year, logarithmic scale). Amber bar: where this company sits.

Compared with similar companies

size, age and company form
Rank among similar companies
GroupGross profitEquity
Companies with fewer than 20 employees69,967 companies in the comparison
No. 69,544of 69,742
Better than 0%
No. 69,784of 69,964
Better than 0%
Same industry and fewer than 20 employees37 companies in the comparison
No. 29of 36
Better than 20%
No. 33of 37
Better than 11%
Companies that are between 5 and 14 years old33,688 companies in the comparison
No. 33,443of 33,588
Better than 0%
No. 33,516of 33,687
Better than 1%
All companies of type ApS66,508 companies in the comparison
No. 66,205of 66,379
Better than 0%
No. 66,327of 66,505
Better than 0%

The rank is calculated among companies in the database with a figure for the latest financial year, and is shown only for groups of at least ten companies.

Compare with the industry

Manufacture of pharmaceutical preparations
Gross profit
  1. Cymab ApS−DKK 5.5m
  2. Novo Nordisk A/SDKK 250.3bn
  3. H. Lundbeck A/SDKK 20.4bn
Net profit
  1. Cymab ApS−DKK 7.6m
  2. Novo Nordisk A/SDKK 102.4bn
  3. H. Lundbeck A/SDKK 3.2bn
Equity
  1. Cymab ApS−DKK 20.2m
  2. Novo Nordisk A/SDKK 194bn
  3. H. Lundbeck A/SDKK 24.9bn
Employees
  1. Cymab ApS2
  2. Novo Nordisk A/S27,279
  3. H. Lundbeck A/S2,261

Latest financial year per company. Choose up to three companies from the largest in the industry.

Owners and group

from the Public Ownership Register
Owners
  • Ebumab Holding ApS100%
Cymab ApS

Management

6 active registrations

Executive management

Executive management at Cymab ApS
NameRoleAppointed
Johan Henrik FaberCEO17/04/2023

Board of directors

Board of directors at Cymab ApS
NameRoleAppointed
Johan Henrik FaberBoard member01/06/2019
Søren Erik BjørnBoard member22/06/2020
Hans Heugh WandallChair of the board17/04/2023
Thomas Dal Stenfeldt BatchelorBoard member17/04/2023
Mads Nikolaj Behrndt-EriksenBoard member17/04/2023
Founders
Ebumab Holding ApS
Former management (13)
Former management at Cymab ApS
NameRoleAppointedResigned
Kurt Flemming HolmstedBoard member10/09/201801/06/2019
Kurt Flemming HolmstedDirector10/09/201801/06/2019
Hans Heugh WandallBoard member10/09/201821/06/2020
Kim Stengaard HolmstedChair of the board10/09/201822/06/2020
Johan Henrik FaberDirector01/06/201916/04/2023
Thomas Dal Stenfeldt BatchelorBoard member01/06/201920/05/2021
Hans Heugh WandallChair of the board22/06/202020/05/2021
Hans Heugh WandallBoard member21/05/202116/04/2023
Hans Heugh WandallCEO21/05/202117/04/2023
Thomas Dal Stenfeldt BatchelorChair of the board21/05/202116/04/2023
Stine Louise Reedtz KjellevDirector17/04/202331/05/2024
Anne Reker CordtBoard member24/06/202406/02/2026
Anne Reker CordtDirector24/06/202406/02/2026

Signing rule: Selskabet tegnes af en direktør i forening med bestyrelsesformanden eller af den samlede bestyrelse.

Address and production units

1 active production units

Ole Maaløes Vej 3
2200 København N

København Municipality · Postcode 2200

Other companies at the address (8)

  • BII Holdings A/SOther financial service activities n.e.c.
  • Skape Bio ApSResearch and experimental development on natural sciences and engineering
  • Agrobiomics ApSResearch and experimental development on natural sciences and engineering
  • Tetrakit Technologies ApSResearch and experimental development on natural sciences and engineering
  • BioColor ApSResearch and experimental development on natural sciences and engineering
Production units
Production unitAddressEmployeesP number
Cymab ApSOle Maaløes Vej 3, 2200 København N21023951386

Purpose

Selskabets formål er at drive virksomhed indenfor forskning, udvikling og markedsføring af farmaceutiske og medicinske præparater samt anden efter bestyrelsens skøn beslægtet virksomhed.

The purpose is quoted from the register in Danish.

Changes year by year

42 registered events
20263 changesaccounts 1 · management 2
  • Annual report for 2025 published
  • Anne Reker Cordt stepped down as director
  • Anne Reker Cordt stepped down as board member
20251 changeaccounts 1
  • Annual report for 2024 published
20244 changesaccounts 1 · management 3
  • Annual report for 2023 published
  • Anne Reker Cordt appointed director
  • Anne Reker Cordt appointed board member
  • Stine Louise Reedtz Kjellev stepped down as director
202311 changesaccounts 1 · name 1 · management 9
  • Annual report for 2022 published
  • Name changed from Ebumab ApS to Cymab ApS
  • Stine Louise Reedtz Kjellev appointed director
  • Mads Nikolaj Behrndt-Eriksen appointed board member
  • Hans Heugh Wandall appointed chair of the board
  • Johan Henrik Faber appointed ceo
  • Thomas Dal Stenfeldt Batchelor appointed board member
  • Hans Heugh Wandall stepped down as ceo
  • Thomas Dal Stenfeldt Batchelor stepped down as chair of the board
  • Hans Heugh Wandall stepped down as board member
  • Johan Henrik Faber stepped down as director
20221 changeaccounts 1
  • Annual report for 2021 published
20216 changesaccounts 1 · management 5
  • Annual report for 2020 published
  • Thomas Dal Stenfeldt Batchelor appointed chair of the board
  • Hans Heugh Wandall appointed board member
  • Hans Heugh Wandall appointed ceo
  • Hans Heugh Wandall stepped down as chair of the board
  • Thomas Dal Stenfeldt Batchelor stepped down as board member
20204 changesmanagement 4
  • Hans Heugh Wandall appointed chair of the board
  • Søren Erik Bjørn appointed board member
  • Kim Stengaard Holmsted stepped down as chair of the board
  • Hans Heugh Wandall stepped down as board member
20196 changesaddress 1 · management 5
  • Moved to Ole Maaløes Vej 3, 2200 København N
  • Johan Henrik Faber appointed director
  • Thomas Dal Stenfeldt Batchelor appointed board member
  • Johan Henrik Faber appointed board member
  • Kurt Flemming Holmsted stepped down as director
  • Kurt Flemming Holmsted stepped down as board member
20186 changesfounded 1 · management 4 · ownership 1
  • Registered as Ebumab ApS
  • Kurt Flemming Holmsted appointed director
  • Kim Stengaard Holmsted appointed chair of the board
  • Hans Heugh Wandall appointed board member
  • Kurt Flemming Holmsted appointed board member
  • Ebumab Holding ApS registered as owner (100%)

Related companies

Same industry in København

See all →

Same people in management

Largest in the industry

See all →

Source and updates

The information comes from the Danish Central Business Register (Danish Business Authority) and from annual reports filed with the Danish Business Authority. Last synchronised 24/10/2026.

View in CVRReport a correction